Navigation Links
Researchers Offer Explanation for Actos Bladder Cancer Risk
Date:7/3/2012

Orlando, FL (PRWEB) July 03, 2012

The Actos Bladder Cancer Center is alerting patients who have taken the drug Actos for their diabetes that researchers have identified an explanation for the drug’s link to bladder cancer. Legal help is still available for those just discovering they have been affected.

Anyone who has experienced symptoms of bladder cancer after taking Actos is encouraged to visit their doctor and speak with a lawyer about their legal rights as soon as possible.

For over a year, drug safety experts have warned that long-term use of Actos may be associated with bladder cancer. On June 10, 2011, CBS News reported that Germany and France banned Actos prescriptions after a study indicated long-term use could increase bladder cancer occurrences by as much as 40%. The FDA followed up on June 15, 2011 by issuing its own alert about the drug.

This April, the Canadian Press also reported that Health Canada had issued a warning after a study there showed a greater than 40% increased risk of bladder cancer from Actos.

Most recently, the British Medical Journal published a study on May 31, 2012 by researchers at McGill University in Montreal showing the increased bladder cancer risks from long-term Actos use may actually be as high as 83%.

The study found that the risk was specific to those taking Actos, and increased with use of the drug for more than two years. Also, this study was the first to specifically propose why Actos may increase risks of bladder cancer.

According to the research team at McGill, a possible explanatory mechanism for Actos bladder cancer risk is chronic irritation of the bladder from crystal formation caused by the drug. However, they cautioned that further research will be needed to establish this as causative.

Anyone who has suffered a bladder cancer or heart attack side effect after taking Actos is urged to speak with a lawyer about their legal options. According to Bloomberg News on March 13, 2012, Takeda Pharmaceuticals could face as many as 10,000 lawsuits in the U.S. from patients suffering serious side effects from their drug.

A federal Judicial Panel has consolidated all Actos lawsuits to a special multi-district federal court in Louisiana. The case is known as In Re: Actos Products Liability Litigation, MDL 2299, U.S. District Court, Western District of Louisiana (Lafayette).

The Actos Resource Center cautions that, while the MDL court will expedite litigation for victims, it is important for anyone affected to choose a lawyer with experience in this specific type of case. The Actos Resource Center works only with qualified Actos lawyers who are actively involved in this litigation and have handled thousands of cases.

For more information on the research, warnings, side effects, a possible actos class action lawsuit and legal options relating to the drug Actos, or to speak with a lawyer, visit http://www.ActosLawsuitUpdate.com.

Read the full story at http://www.prweb.com/releases/actos/lawsuit/prweb9663606.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. NIH awards $20 million over 5 years to train next generation of global health researchers
2. Researchers develop a new cell and animal model of inflammatory breast cancer
3. Researchers uncover a viable way for colorectal cancer patients to overcome drug resistance
4. Researchers Find Gene Mutations That May Be a Key to Autism
5. Researchers find evidence of banned antibiotics in poultry products
6. NJ stroke researchers report advances in spatial neglect research at AAN Conference
7. Autism by the numbers: Yale researchers examine impact of new diagnostic criteria
8. Researchers Map Brain Regions Linked to Intelligence
9. Researchers ID Genes That May Determine Mental Illness
10. Researchers Develop Blood Test for Depression
11. University of Cincinnati researchers win $3.7M grant from US Department of Defense
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... 27, 2016 , ... Quality metrics are proliferating in cancer care, and are ... the eye of the beholder, according to experts who offered insights and commentary in ... Managed Care. For the full issue, click here . , For the American ...
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... ... fertility once they have been diagnosed with endometriosis. These women need a treatment ... also require a comprehensive approach that can help for preservation of fertility and ...
(Date:6/25/2016)... Lewisville, TX (PRWEB) , ... June 25, 2016 , ... ... in the United States, named Dr. Sesan Ogunleye, as the Medical Director of its ... be the facility Medical Director of our new Mesquite location,” said Dr. James M. ...
(Date:6/24/2016)... , ... June 24, 2016 , ... A recent ... most people are unfamiliar with. The article goes on to state that individuals are ... many of these less common operations such as calf and cheek reduction. The Los ...
(Date:6/24/2016)... Fla. (PRWEB) , ... June 24, 2016 , ... Global ... Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition ... Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this year’s ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... DUBLIN , June 27, 2016 Jazz ... the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act ... proposed acquisition of Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: ... 11:59 p.m. (Eastern Daylight Time). As previously ... entered into a definitive merger agreement under which Jazz ...
(Date:6/24/2016)... June 24, 2016  Global Blood Therapeutics, Inc. (GBT) ... developing novel therapeutics for the treatment of grievous ... the closing of its previously announced underwritten public ... the public offering price of $18.75 per share. ... offered by GBT. GBT estimates net proceeds from ...
(Date:6/24/2016)... , June 24, 2016 Dehaier Medical Systems ... "Company"), which develops, markets and sells medical devices and ... , signed a strategic cooperation agreement with Hongyuan Supply ... Supply Chain") on June 20, 2016, to develop Dehaier,s ... strategic cooperation agreement, Dehaier will leverage Hongyuan Supply Chain,s ...
Breaking Medicine Technology: